Abstract
GV129606 is a new parenteral trinem antibiotic belonging to the beta-lactam class. It combines broad-spectrum activity (against gram-negative and -positive bacteria, aerobes and anaerobes), with high potency and resistance to beta-lactamases. Comparative in vitro and in vivo antibacterial activities were determined for GV129606 against more than 400 recent clinical isolates (aerobes, including beta-lactamase producers, and anaerobes), using representative antibacterial agents (meropenem, piperacillin, ceftazidime, cefpirome, ciprofloxacin, and gentamicin for aerobes and metronidazole, cefoxitin, piperacillin, and clindamycin for anaerobes). Against methicillin-susceptible staphylococci and streptococci, GV129606 and meropenem were the most active of the drugs tested. GV129606 showed an MIC for 90% of strains tested (MIC90) ranging from < or =0.015 to 0.06 microg/ml against methicillin-susceptible staphylococci and Streptococcus sanguis, Streptococcus pyogenes, and Streptococcus agalactiae. Against penicillin-susceptible and -resistant Streptococcus pneumoniae isolates, GV129606, meropenem, and cefpirome showed MIC90s of < or =0.015 and 1 microg/ml, respectively. Meropenem was the most active compound against members of the family Enterobacteriaceae with MIC90s of < or =0.5 microg/ml. Against these species, GV129606 possessed activity superior to those of piperacillin, ceftazidime, cefpirome, and gentamicin, with MIC90s of < or =8 microg/ml, but its activity was two- to sixfold less than that of ciprofloxacin (with the exception of Proteus rettgeri and Providencia stuartii). Haemophilus spp., Moraxella catarrhalis, Neisseria gonorrhoeae, and Pseudomonas aeruginosa were also included in the spectrum of GV129606. GV129606 showed good antianaerobe activity, similar to metronidazole. It was stable against all clinically relevant beta-lactamases (similar to meropenem). The in vitro activity was confirmed in vivo against septicemia infections induced in mice by selected gram-positive and -negative bacteria with 50% effective doses (ED50s) of < or =0.05 and < or =0.5 mg/kg of body weight/dose, respectively. GV129606 was as effective as meropenem against septicemia in mice caused by ceftazidime-resistant Pseudomonas aeruginosa, exhibiting an ED50 of 0.33 mg/kg/dose.
Full Text
The Full Text of this article is available as a PDF (165.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bush K., Jacoby G. A., Medeiros A. A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995 Jun;39(6):1211–1233. doi: 10.1128/aac.39.6.1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Di Modugno E., Erbetti I., Ferrari L., Galassi G., Hammond S. M., Xerri L. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria. Antimicrob Agents Chemother. 1994 Oct;38(10):2362–2368. doi: 10.1128/aac.38.10.2362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Doern G. V., Pierce G., Brueggemann A. B. In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diagn Microbiol Infect Dis. 1996 Sep;26(1):39–42. doi: 10.1016/s0732-8893(96)00173-3. [DOI] [PubMed] [Google Scholar]
- Jones R. N. The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Diagn Microbiol Infect Dis. 1992 Feb;15(2 Suppl):3S–10S. [PubMed] [Google Scholar]
- Neu H. C. The crisis in antibiotic resistance. Science. 1992 Aug 21;257(5073):1064–1073. doi: 10.1126/science.257.5073.1064. [DOI] [PubMed] [Google Scholar]
- Sanders C. C. beta-Lactamases of gram-negative bacteria: new challenges for new drugs. Clin Infect Dis. 1992 May;14(5):1089–1099. doi: 10.1093/clinids/14.5.1089. [DOI] [PubMed] [Google Scholar]
- Silver L. L., Bostian K. A. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob Agents Chemother. 1993 Mar;37(3):377–383. doi: 10.1128/aac.37.3.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spangler S. K., Jacobs M. R., Appelbaum P. C. MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents. Antimicrob Agents Chemother. 1997 Jan;41(1):148–155. doi: 10.1128/aac.41.1.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spratt B. G. Resistance to antibiotics mediated by target alterations. Science. 1994 Apr 15;264(5157):388–393. doi: 10.1126/science.8153626. [DOI] [PubMed] [Google Scholar]
- Swartz M. N. Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2420–2427. doi: 10.1073/pnas.91.7.2420. [DOI] [PMC free article] [PubMed] [Google Scholar]